Tradestie Institutional Equity Comparison Engine

NBP vs ALLO โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

NBP Overall Edge

NBP Captures Institutional Edge (4โ€“0 Pillars ยท 5โ€“3 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to NBP (NBP) driven by superior Valuation, Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, NBP trades at 2.7x Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus ALLO at N/M Forward P/E and -4172.6% operating margin (-100.0% YoY). In options structure, NBP sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against ALLO sits in BREAKDOWN (100th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner NBP
NBP 2.7x vs ALLO N/M Fwd P/E
Growth & Margin Winner NBP
Op Margin 0.0% vs -4172.6% ยท YoY +0.0% vs -100.0%
Momentum & Technical Winner NBP
1Y -81.0% vs -33.7% ยท 52W Pos 0% vs 1%
Options & Structure Winner NBP
UNCLASSIFIED (N/A IV) vs BREAKDOWN (100th %ile IV)
NBP US Equity
NBP
Institutional Equity
$0.79
-6.66% 1D
Market Cap $96.3M
1M Return -37.04%
1Y Return -80.98%
Forward P/E 2.7x
Unified AI Score
51.9 / 100 HOLD
Tech 60.0 Fund 50.0 Flow 50.0 Mom 55.0
ALLO NASDAQ
Allogene Therapeutics, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$0.80
-5.09% 1D
Market Cap $286.5M
1M Return -39.24%
1Y Return -33.67%
Forward P/E N/M
Unified AI Score
42.6 / 100 HOLD
Tech 25.0 Fund 49.0 Flow 70.0 Mom 59.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: NBP -80.98% ALLO -33.67% Spread: +47.31 pp (ALLO Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
NBP TTM Op. Margin: 0.0% ALLO TTM Op. Margin: -4172.6%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on NBP vs ALLO. Trailing 12-month operating profitability (NBP 0.0% vs ALLO -4172.6%) and valuation multiples (NBP 2.7x vs ALLO N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: NBP (5) vs ALLO (3)
Institutional Metric NBP ALLO Criterion Row Winner
Market Capitalization Scale $96.3M $286.5M Larger Scale ALLO
Trailing P/E Ratio Valuation 2.7x N/M Lower Multiple NBP
Forward P/E Ratio Valuation 2.7x N/M Lower Multiple NBP
Revenue Growth (YoY) Growth +0.0% -100.0% Higher Growth NBP
Operating Margin (TTM) Profitability 0.0% -4172.6% Higher Margin NBP
Net Profit Margin Profitability 0.0% 0.0% Higher Margin Tie
Return on Equity (ROE) Capital Efficiency -59.1% -49.3% Higher ROE ALLO
52-Week Range Position Momentum 0% ($1โ€“$5) 1% ($1โ€“$4) Stronger Trend Tie
Beta / 30D Volatility Risk Regime 1.66ฮฒ ยท 81% Vol 1.87ฮฒ ยท 79% Vol Lower Realized Risk ALLO
Unified Institutional Score Composite Signal 51.9 / 100 (HOLD) 42.6 / 100 (HOLD) Higher Composite NBP

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full NBP vs ALLO Buy Guide
NBP UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live NBP Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
ALLO BREAKDOWN
151d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 100th %ile
IV Regime Extreme (>80th %ile)
Live ALLO Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither NBP nor ALLO registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.